TCGA-44-2665-01A-01R-A278-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- UV_RESPONSE_DN+0.340
- ANDROGEN_RESPONSE+0.290
- KRAS_SIGNALING_UP+0.200
- TGF_BETA_SIGNALING+0.180
- INTERFERON_GAMMA_RESPONSE+0.150
- INTERFERON_ALPHA_RESPONSE+0.140
- INFLAMMATORY_RESPONSE+0.090
- ANGIOGENESIS+0.070
Top 10 suppressed
- MYC_TARGETS_V2-0.420
- CHOLESTEROL_HOMEOSTASIS-0.360
- APICAL_SURFACE-0.340
- KRAS_SIGNALING_DN-0.340
- UV_RESPONSE_UP-0.330
- ESTROGEN_RESPONSE_LATE-0.320
- E2F_TARGETS-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- MYOGENESIS-0.280
- P53_PATHWAY-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-3918-01A-01R-A278-07 | — | cohortMD2 | 0.811 |
| 2 | TCGA-E9-A24A-01A-11R-A169-07 | — | B | 0.792 |
| 3 | SRR6013566 | — | cohortMD2 | 0.786 |
| 4 | TCGA-44-2665-01B-06R-A277-07 | — | cohortMD2 | 0.768 |
| 5 | SRR25617900 | — | A | 0.764 |
| 6 | TCGA-44-6147-01A-11R-A278-07 | — | cohortMD2 | 0.762 |
| 7 | MNG864 | — | — | 0.753 |
| 8 | R404 | — | — | 0.752 |
| 9 | TCGA-44-6775-01A-11R-A278-07 | — | cohortMD2 | 0.747 |
| 10 | SRR6013569 | — | cohortMD2 | 0.737 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.090 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |